Trial · NCT02460224
Adverse events24,559
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 24,559Pages stop at row 10,000
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 1 mg/kg Q2W | 3 | 13 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 3 mg/kg Q2W | 3 | 12 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 5 mg/kg Q2W | 2 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 10 mg/kg Q2W | 2 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 15 mg/kg Q2W | 2 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 240 mg Q2W | 3 | 25 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 400 mg Q2W | 6 | 24 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 1 mg/kg Q2W-JP | 2 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 240 mg Q2W-JP | 3 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 400 mg Q2W-JP | 0 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 3 mg/kg Q4W | 1 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 5 mg/kg Q4W | 3 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 10 mg/kg Q4W | 3 | 11 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 400 mg Q4W | 0 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W | 2 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W | 1 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W | 1 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W | 1 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W | 0 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W | 5 | 20 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02460224/events